# A Study to Evaluate the Performance and Safety of Artelac Rebalance® Versus Vismed in the Management of Dry Eye

> **NCT01791426** · NA · WITHDRAWN · sponsor: **Bausch & Lomb Incorporated**

## Conditions studied

- Dry Eye

## Interventions

- **DEVICE:** Artelac Rebalance
- **DEVICE:** Vismed

## Key facts

- **NCT ID:** NCT01791426
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-05
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Adjustment of company focus due to acquision by Valeant Pharmaceuticals
- **Last updated:** 2013-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01791426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01791426, "A Study to Evaluate the Performance and Safety of Artelac Rebalance® Versus Vismed in the Management of Dry Eye". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01791426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*